Pfizer’s rejig made for growth, but it’s also handy for a future split: executives Pfizer’s new three-unit structure may be all about driving growth for now. But don’t count out […]
Active Bio and Teva’s laquinimod fails once more, now in Huntington’s disease Active Biotech and Teva delivered more bad news from their clinical development of laquinimod, this time from a […]
Thanks to Genzyme—and no thanks to vaccines or diabetes—Sanofi is treading water As much as Sanofi has struggled with diabetes and generic drugs the past few years, it could typically […]
European backing for Merck’s Keytruda rubs salt in Bristol-Myers’ wounds Merck’s Keytruda is one step closer to extending its dominance in the all-important previously untreated lung cancer market. On Monday, […]
Nebraska lawmaker urges Pfizer to sue over use of its drugs in lethal injection procedure “Time is of the essence,” a Nebraska lawmaker wrote to Pfizer in an attempt to […]
After its recent funding round, HiFiBiO pens Takeda R&D collaboration HiFiBiO Therapeutics has signed a deal with Japanese Big Pharma and biotech friend Takeda to work on antibody therapies for […]
Freshly funded IFM Therapeutics defines emerging target for fighting inflammatory disease Just two weeks after hauling in a $31 million series A funding round to form a new subsidiary, Boston-based […]
Teva’s picked an address in Parsippany, New Jersey, and the dirt’s about to fly Teva now knows where it’s headed in New Jersey, but it’s still got plenty of work […]
As Humira competition nears, AbbVie’s Imbruvica and Mavyret pick up steam AbbVie is bracing for European biosimilar competition to Humira, but the drug is still continuing its upward trajectory. In […]
Achaogen wields ax on R&D, C-suite as antibiotic launch gets underway The impact of Achaogen’s narrower-than-expected label for antibiotic Zemdri is now apparent: The biotech has slashed 28% of its […]